Marker Therapeutics (MRKR)
Develops non-genetically modified multi-antigen T-cell therapies for lymphoma, pancreatic cancer, AML, and MDS.
$1.21
vs last close+0.01 (+0.83%)
Something off on this page? Send us feedback.
Next report
Nov 12, 26
in 51 days
EPS estimate
−$0.12
Revenue estimate
$2.1M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.42−$0.40−$0.29−$0.12−$0.10−$0.16−$0.09Pending
Estimate−$0.22−$0.66−$0.30−$0.36−$0.21−$0.18−$0.13−$0.12
Surprise−90.9%+39.4%+4.6%+66.7%+52.4%+11.1%+29.1%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$2.3M$349.1K$861.2K$1.2M$1.1M$800.0K$700.0KPending
Estimate$1.2M$174.6K$430.6K$723.0K$682.1K$783.9K$660.7K$2.1M
Surprise+84.1%+100.0%+100.0%+70.5%+61.3%+2.1%+6.0%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.23 | — | — |
| Sep 2027 | −$0.21 | — | — |
| Jun 2027 | −$0.25 | — | — |
| Mar 2027 | −$0.22 | — | — |
| Dec 2026 | −$0.22 | — | — |
| Nov 2026 | −$0.12 | — | — |
| Aug 2026 | −$0.13 | −$0.09 | +29.1% |
| May 2026 | −$0.18 | −$0.16 | +11.1% |
| Mar 2026 | −$0.21 | −$0.10 | +52.4% |
| Nov 2025 | −$0.36 | −$0.12 | +66.7% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Apr 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.23 | — | — | $1.2M | — | — | — |
| Sep 2027 | −$0.21 | — | — | $1.2M | — | — | — |
| Jun 2027 | −$0.25 | — | — | $1.2M | — | — | — |
| Mar 2027 | −$0.22 | — | — | $1.2M | — | — | — |
| Dec 2026 | −$0.22 | — | — | $715.3K | — | — | — |
| Nov 12, 2026 | −$0.12 | — | — | $2.1M | — | — | — |
| Aug 14, 2026 | −$0.13 | −$0.09 | +29.1% | $660.7K | $700.0K | +6.0% | +2.7% |
| May 15, 2026 | −$0.18 | −$0.16 | +11.1% | $783.9K | $800.0K | +2.1% | −2.1% |
| Mar 18, 2026 | −$0.21 | −$0.10 | +52.4% | $682.1K | $1.1M | +61.3% | −1.5% |
| Nov 13, 2025 | −$0.36 | −$0.12 | +66.7% | $723.0K | $1.2M | +70.5% | −5.5% |
| Aug 14, 2025 | |||||||
| May 15, 2025 | |||||||
| Mar 31, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Aug 14, 2024 | |||||||
| May 15, 2024 | |||||||
| Mar 26, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 14, 2023 | |||||||
| May 16, 2023 | |||||||
| Mar 22, 2023 | |||||||
| Nov 10, 2022 | |||||||
| Aug 11, 2022 | |||||||
| May 13, 2022 | |||||||
| Mar 17, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 10, 2021 | |||||||
| May 12, 2021 | |||||||
| Mar 9, 2021 | |||||||
| Nov 9, 2020 | |||||||
| Aug 10, 2020 | |||||||
| May 11, 2020 | |||||||
| Mar 12, 2020 | |||||||
| Nov 12, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 9, 2019 | |||||||
| Mar 15, 2019 | |||||||
| Nov 13, 2018 | |||||||
| Aug 9, 2018 | |||||||
| May 15, 2018 | |||||||
| Mar 23, 2018 | |||||||
| Nov 14, 2017 | |||||||
| Aug 7, 2017 | |||||||
| May 5, 2017 | |||||||
| Mar 14, 2017 | |||||||
| Nov 4, 2016 | |||||||
| Aug 15, 2016 | |||||||
| May 16, 2016 | |||||||
| Apr 14, 2016 | |||||||
| Nov 16, 2015 | |||||||
| Aug 14, 2015 |